Drug Trial Radar · NCT00312494
3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects
Last checked: Nov 20, 2026Latest source record: Mar 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
680
Actual
Start
Apr 2006
Primary completion
Dec 2008
Study completion Dec 2008
Sponsor
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
- Sponsor type
- Industry
- First posted
- Apr 10, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
3-week study to evaluate efficacy and safety of ziprasidone with either lithium or divalproex in acutely manic subjects
Conditions
- Bipolar Disorder
Interventions
PlaceboDrug
Placebo with mood stabilizer (either lithium or divalproex)
ZiprasidoneDrug
Flexible dosing, 20-40mg BID, with a mood stabilizer (either lithium or divalproex)
ZiprasidoneDrug
Flexible dosing, 60-80mg BID, with a mood stabilizer (either lithium or divalproex)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 3 in Young Mania Rating Scale (YMRS)Time frame: Baseline, Week 3
Locations
66 sites in 1 country. Site status is shown where the registry gives one.
Pfizer Investigational Site
Dothan, Alabama
Pfizer Investigational Site
Scottsdale, Arizona
Pfizer Investigational Site
Little Rock, Arkansas
Pfizer Investigational Site
Cerritos, California
Pfizer Investigational Site
Costa Mesa, California
Pfizer Investigational Site
Escondido, California
Pfizer Investigational Site
Glendale, California
Pfizer Investigational Site
Huntington Beach, California
Pfizer Investigational Site
Los Angeles, California
Pfizer Investigational Site
Los Angeles, California
Pfizer Investigational Site
National City, California
Pfizer Investigational Site
Oceanside, California
Pfizer Investigational Site
San Diego, California
Pfizer Investigational Site
San Diego, California
Pfizer Investigational Site
San Diego, California
Pfizer Investigational Site
Torrance, California
Pfizer Investigational Site
Hartford, Connecticut
Pfizer Investigational Site
New Britain, Connecticut
Pfizer Investigational Site
DeLand, Florida
Pfizer Investigational Site
Fort Lauderdale, Florida
Pfizer Investigational Site
Fort Lauderdale, Florida
Pfizer Investigational Site
Gainesville, Florida
Pfizer Investigational Site
Hollywood, Florida
Pfizer Investigational Site
Jacksonville, Florida
Pfizer Investigational Site
Lauderhill, Florida
Pfizer Investigational Site
North Miami, Florida
Pfizer Investigational Site
Atlanta, Georgia
Pfizer Investigational Site
Honolulu, Hawaii
Pfizer Investigational Site
Des Plaines, Illinois
Pfizer Investigational Site
Hoffman Estates, Illinois
Pfizer Investigational Site
Hoffman Estates, Illinois
Pfizer Investigational Site
Schaumburg, Illinois
Pfizer Investigational Site
Greenwood, Indiana
Pfizer Investigational Site
Prairie Village, Kansas
Pfizer Investigational Site
Glen Burnie, Maryland
Pfizer Investigational Site
Flowood, Mississippi
Pfizer Investigational Site
Kansas City, Missouri
Pfizer Investigational Site
Saint Charles, Missouri
Pfizer Investigational Site
St Louis, Missouri
Pfizer Investigational Site
St Louis, Missouri
Showing 40 of 66 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.